Otezla FDA Approval History
Last updated by Judith Stewart, BPharm on July 20, 2019.
FDA Approved: Yes (First approved March 21, 2014)
Brand name: Otezla
Generic name: apremilast
Dosage form: Tablets
Company: Celgene Corporation
Treatment for: Psoriatic Arthritis, Plaque Psoriasis, Behcet's Disease
Otezla (apremilast) is a phosphodiesterase 4 (PDE4) inhibitor indicated for the treatment of psoriatic arthritis, plaque psoriasis, and oral ulcers associated with Behçet’s Disease.
Development timeline for Otezla
|Sep 8, 2022||Amgen Announces Positive New Data for Otezla|
|Dec 20, 2021||Approval FDA Approves Otezla (apremilast) for the Treatment of Adult Patients with Plaque Psoriasis, Regardless of Severity Level|
|Jul 19, 2019||Approval FDA Approves Otezla (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease|
|Sep 23, 2014||Approval FDA Approves Otezla (apremilast) for Moderate to Severe Plaque Psoriasis|
|Mar 21, 2014||Approval FDA Approves Otezla (apremilast) to Treat Psoriatic Arthritis|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.